Combined modality therapy for stage III(MO) non-oat cell bronchogenic carcinoma

J. D. Bitran, R. K. Desser, T. DeMeester, C. M. Shapiro, A. Billings, L. Rubenstein, R. Evans, M. Colman, C. Y. Rao, M. Griem, H. M. Golomb

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


Thirty-nine patients with stage III (MO) non-oat cell bronchogenic carcinoma (NOBC) were treated with combined modality therapy: radiation therapy and chemotherapy with cyclophosphamide, adriamycin, methotrexate, and procarbazine. The median survival for all patients treated was 9.6 months compared to 6.4 months for historical controls (P = 0.015). Patients who responded to the treatment program had a significantly longer survival (median, 15.2 months) compared to nonresponders and historical controls (P < 0.005). It is concluded that combined modality therapy is moderately effective therapy in stage III (MO) NOBC.

Original languageEnglish (US)
Pages (from-to)327-332
Number of pages6
JournalCancer Treatment Reports
Issue number3
StatePublished - 1978
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Combined modality therapy for stage III(MO) non-oat cell bronchogenic carcinoma'. Together they form a unique fingerprint.

Cite this